



Revision date: 04-Jan-2017 Version: 1.0 Page 1 of 9

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Metoclopramide Injection (Hospira, Inc.)

Trade Name: Not established Synonyms: Metoclopramidum

Chemical Family: Mixture

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used for nausea and vomiting (antiemetic)

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company 275 North Field Drive Lake Forest, Illinois 60045

1-800-879-3477

Hospira UK Limited

Horizon Honey Lane Hurley

Maidenhead, SL6 6RJ United Kingdom

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

Emergency telephone number: CHEMTREC (24 hours): 1-800-42

CHEMTREC (24 hours): 1-800-424-9300
Contact E-Mail: pfizer-MSDS@pfizer.com

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification Not classified as hazardous

Label Elements

Signal Word: Not Classified

Hazard Statements: Not classified in accordance with international standards for workplace safety.

Other Hazards An Occupational Exposure Value has been established for one or more of the ingredients (see

Section 8).

Note: This document has been prepared in accordance with standards for workplace safety, which

requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases.

Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Material Name: Metoclopramide Injection (Hospira, Inc.) Page 2 of 9 Revision date: 04-Jan-2017 Version: 1.0

3. COMPOSITION / INFORMATION ON INGREDIENTS						
Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%		
Metoclopramide	364-62-5	206-662-9	Acute Tox 4 (H302)	0.5		
Sodium hydroxide	1310-73-2	215-185-5	Skin Corr.1A (H314)	**		
HYDROCHLORIC ACID	7647-01-0	231-595-7	Skin Corr.1B (H314) STOT SE 3 (H335)	**		

Ingredient	CAS Number	EU EINECS/ELINCS	GHS Classification	%
		List		
Water for injection	7732-18-5	231-791-2	Not Listed	*
Sodium chloride	7647-14-5	231-598-3	Not Listed	*

Additional Information: * Proprietary

** to adjust pH

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this

mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact: If irritation occurs or persists, get medical attention. Rinse thoroughly with plenty of water, also

under the eyelids.

Wash exposed area with soap and water, remove contaminated clothing and obtain medical **Skin Contact:**

assistance if irritation occurs.

Ingestion: Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not

induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation: Due to the nature of this material first aid is not normally required.

Most Important Symptoms and Effects, Both Acute and Delayed

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Symptoms and Effects of

Exposure: Identification and/or Section 11 - Toxicological Information.

Medical Conditions Aggravated by Exposure:

None known

Indication of the Immediate Medical Attention and Special Treatment Needed

None Notes to Physician:

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO2, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion May emit toxic fumes of carbon monoxide, carbon dioxide, nitrogen oxides, hydrogen chloride

Products: and other chlorine-containing compounds.

Fire / Explosion Hazards: Not applicable

Material Name: Metoclopramide Injection (Hospira, Inc.)

Revision date: 04-Jan-2017 Version: 1.0

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Large Spills:

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill

Collecting: area thoroughly.

Additional Consideration for Non-essential personnel should be evacuated from affected area. Report emergency

situations immediately. Clean up operations should only be undertaken by trained personnel.

Page 3 of 9

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash thoroughly after handling. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product used for nausea and vomiting (antiemetic)

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

Metoclopramide

Pfizer OEL TWA-8 Hr: 40 µg/m³

Sodium chloride

Latvia OEL - TWA 5 mg/m³
Lithuania OEL - TWA 5 mg/m³

Sodium hydroxide

ACGIH Ceiling Threshold Limit: 2 mg/m^3 Australia PEAK 2 mg/m³ 2 mg/m³ **Austria OEL - MAKs Bulgaria OEL - TWA** 2.0 mg/m3 Czech Republic OEL - TWA 1 mg/m^3 Estonia OEL - TWA 1 mg/m^3 France OEL - TWA 2 ma/m3 **Greece OEL - TWA** 2 mg/m³ **Hungary OEL - TWA** 2 mg/m^3 Japan - OELs - Ceilings 2 mg/m^3

Material Name: Metoclopramide Injection (Hospira, Inc.)

Page 4 of 9

Revision date: 04-Jan-2017 Version: 1.0

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

 Latvia OEL - TWA
 0.5 mg/m³

 OSHA - Final PELS - TWAs:
 2 mg/m³

 Poland OEL - TWA
 0.5 mg/m³

 Slovakia OEL - TWA
 2 mg/m³

 Slovenia OEL - TWA
 2 mg/m³

 Sweden OEL - TWAs
 1 mg/m³

 Switzerland OEL - TWAs
 2 mg/m³

HYDROCHLORIC ACID

 ACGIH Ceiling Threshold Limit:
 2 ppm

 Australia PEAK
 5 ppm

 7.5 mg/m³
 7.5 mg/m³

 Austria OEL - MAKs
 5 ppm

 8 mg/m³
 5 ppm

 8 mg/m³
 8 mg/m³

 $\begin{tabular}{lll} \bf Bulgaria~OEL-TWA & 5~ppm & \\ 8.0~mg/m^3 \\ \bf Cyprus~OEL-TWA & 5~ppm & \\ 8~mg/m^3 & \\ \end{tabular}$

Czech Republic OEL - TWA8 mg/m³Estonia OEL - TWA5 ppm
8 mg/m³

 $\begin{array}{ccc} \textbf{Germany - TRGS 900 - TWAs} & 2 \text{ ppm} \\ & 3 \text{ mg/m}^3 \\ \textbf{Germany (DFG) - MAK} & 2 \text{ ppm} \\ & 3.0 \text{ mg/m}^3 \end{array}$

 Greece OEL - TWA
 5 ppm

 7 mg/m³

 Hungary OEL - TWA
 8 mg/m³

 Ireland OEL - TWAs
 5 ppm

8 mg/m³

Italy OEL - TWA 5 ppm 8 mg/m³

Japan - OELs - Ceilings2 ppm3.0 mg/m³

 Latvia OEL - TWA
 5 ppm

 8 mg/m³
 5 ppm

 Lithuania OEL - TWA
 5 ppm

8 mg/m³ **Luxembourg OEL - TWA**5 ppm

Malta OEL - TWA 5 ppm

 8 mg/m³

 Netherlands OEL - TWA
 8 mg/m³

 Poland OEL - TWA
 5 mg/m³

 Portugal OEL - TWA
 5 ppm

 8 mg/m³
 8 mg/m³

 Romania OEL - TWA
 5 ppm

8 mg/m³
Slovakia OEL - TWA 5 ppm

Slovakia OEL - TWA 5 ppm 8.0 mg/m³

D700070

Material Name: Metoclopramide Injection (Hospira, Inc.)

Revision date: 04-Jan-2017

Version: 1.0

Version date: 64 dan 2011

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Slovenia OEL - TWA 5 ppm

8 mg/m³
Spain OEL - TWA 5 ppm

7.6 mg/m³ 2 ppm

3.0 mg/m³ **Vietnam OEL - TWAs**5 mg/m³

Sodium chloride

Pfizer Occupational Exposure OEB 1 (control exposure to the range of 1000ug/m³ to 3000ug/m³)

Band (OEB):

Switzerland OEL -TWAs

Exposure Controls

Engineering Controls: Engineering controls should be used as the primary means to control exposures. General

room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne

contamination levels below the exposure limits listed above in this section.

Personal Protective

Equipment: protective equipment (PPE).

Hands: Impervious gloves (e.g. Nitrile, etc.) are recommended if skin contact with drug product is

possible and for bulk processing operations. (Protective gloves must meet the standards in

Refer to applicable national standards and regulations in the selection and use of personal

accordance with EN374, ASTM F1001 or international equivalent.)

Eyes: Wear safety glasses or goggles if eye contact is possible. (Eye protection must meet the

standards in accordance with EN166, ANSI Z87.1 or international equivalent.)

Skin: Impervious protective clothing is recommended if skin contact with drug product is possible and

for bulk processing operations. (Protective clothing must meet the standards in accordance

with EN13982, ANSI 103 or international equivalent.)

Respiratory protection: Under normal conditions of use, if the applicable Occupational Exposure Limit (OEL) is

exceeded, wear an appropriate respirator with a protection factor sufficient to control exposures to below the OEL (e.g. particulate respirator with a half mask, P3 filter). (Respirators must meet the standards in accordance with EN140, EN143, ASTM F2704-10 or international

Mixture

equivalent.)

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:Liquid solutionColor:Clear, colorlessOdor:No data available.Odor Threshold:No data available.

Molecular Formula: Mixture Molecular Weight:

Solvent Solubility:

Water Solubility:

PH:

No data available

No data available.

No data available.

No data available.

No data available.

No data available

No data available

No data available.

Partition Coefficient: (Method, pH, Endpoint, Value)

Metoclopramide
No data available
Water for injection
No data available
Sodium chloride
No data available
Sodium hydroxide

No data available

Material Name: Metoclopramide Injection (Hospira, Inc.) Page 6 of 9 Revision date: 04-Jan-2017

Version: 1.0

9. PHYSICAL AND CHEMICAL PROPERTIES

HYDROCHLORIC ACID

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available Vapor Pressure (kPa): No data available No data available Vapor Density (g/ml): **Relative Density:** No data available Viscosity: No data available

Flammablity:

Autoignition Temperature (Solid) (°C): No data available Flammability (Solids): No data available Flash Point (Liquid) (°C): No data available Upper Explosive Limits (Liquid) (% by Vol.): No data available Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: None **Conditions to Avoid:** None known

As a precautionary measure, keep away from strong oxidizers **Incompatible Materials:**

Hazardous Decomposition No data available

Products:

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the individual

Short Term: Accidental ingestion may cause effects similar to those seen in clinical use.

Known Clinical Effects: Therapeutic use of this substance has resulted in weakness, dizziness, drowsiness, ataxia,

confusion, tremors, headache, and gastrointestinal disturbances. As with all antipsychotic agents, tardive dyskinesia may appear. This syndrome is characterized by rhythmical

involuntary movements of the tongue, face, mouth, or jaw. Hypersensitivity reactions may also

occur in susceptible individuals.

Acute Toxicity: (Species, Route, End Point, Dose)

Metoclopramide

Rat Oral LD 50 750 mg/kg Mouse Oral LD 50 270mg/kg Intraperitoneal LD 50 114mg/kg

Sodium chloride

Rat Oral LD50 3000 mg/kg Mouse Oral LD50 4000 mg/kg

Sodium hydroxide

Material Name: Metoclopramide Injection (Hospira, Inc.)

Page 7 of 9

Revision date: 04-Jan-2017 Version: 1.0

11. TOXICOLOGICAL INFORMATION

Mouse IP LD50 40 mg/kg

HYDROCHLORIC ACID

Rat Oral LD 50 238-277 mg/kg

Irritation / Sensitization: (Study Type, Species, Severity)

Sodium chloride

Eye Irritation Rabbit Moderate Skin Irritation Rabbit Mild

Sodium hydroxide

Eye Irritation Rabbit Severe Skin Irritation Rabbit Severe

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Metoclopramide

Embryo / Fetal Development Oral 10 mg/kg/day NOEL Not teratogenic Rat Embryo / Fetal Development Rabbit Oral 10 mg/kg/day NOEL Not Teratogenic Embryo / Fetal Development Mouse Oral 10 mg/kg/day NOEL Not Teratogenic Intravenous Embryo / Fetal Development Rabbit 10 mg/kg NOEL Not Teratogenic

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

HYDROCHLORIC ACID

Bacterial Mutagenicity (Ames) Salmonella Negative

In Vivo Micronucleus Rat Negative

<u>Carcinogen Status:</u> None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA.

HYDROCHLORIC ACID

IARC: Group 3 (Not Classifiable)

12. ECOLOGICAL INFORMATION

Environmental Overview: Environmental properties have not been investigated. Releases to the environment should be

avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

Material Name: Metoclopramide Injection (Hospira, Inc.)

Revision date: 04-Jan-2017

Version: 1.0

Nevision date: 04-5an-2017

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State

specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Metoclopramide

CERCLA/SARA 313 Emission reporting

California Proposition 65

Not Listed

Standard for the Uniform Scheduling
for Drugs and Poisons:

Schedule 4

EU EINECS/ELINCS List

Not Listed

Schedule 3

Schedule 4

206-662-9

Water for injection

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

REACH - Annex IV - Exemptions from the

Present

Present

obligations of Register:

EU EINECS/ELINCS List 231-791-2

Sodium chloride

CERCLA/SARA 313 Emission reporting

California Proposition 65

Inventory - United States TSCA - Sect. 8(b)

Australia (AICS):

Present

EU EINECS/ELINCS List

Not Listed

Not

Sodium hydroxide

CERCLA/SARA 313 Emission reporting Not Listed

5000 lb

Material Name: Metoclopramide Injection (Hospira, Inc.)

Revision date: 04-Jan-2017

Version: 1.0

15. REGULATORY INFORMATION

CERCLA/SARA Hazardous Substances 1000 lb and their Reportable Quantities: 454 kg **California Proposition 65** Not Listed Inventory - United States TSCA - Sect. 8(b) Present Australia (AICS): Present Standard for the Uniform Scheduling Schedule 5 for Drugs and Poisons: Schedule 6 **EU EINECS/ELINCS List** 215-185-5

HYDROCHLORIC ACID

CERCLA/SARA 313 Emission reporting 1.0 %
CERCLA/SARA Hazardous Substances 5000 lb
and their Reportable Quantities: 2270 kg
CERCLA/SARA - Section 302 Extremely Hazardous 500 lb

CERCLA/SARA - Section 302 Extremely Hazardous

Substances EPCRA RQs

California Proposition 65
Inventory - United States TSCA - Sect. 8(b)
Australia (AICS):
Standard for the Uniform Scheduling
for Drugs and Poisons:
Schedule 6
EU EINECS/ELINCS List

Not Listed
Present
Schedule 5
Schedule 5
Schedule 6
231-595-7

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Acute toxicity, oral-Cat.4; H302 - Harmful if swallowed

Skin corrosion/irritation-Cat.1A; Skin corrosion/irritation-Cat.1B; H314 - Causes severe skin burns and eye damage Specific target organ toxicity, single exposure; Respiratory tract irritation-Cat.3; H335 - May cause respiratory irritation

Data Sources: Safety data sheets for individual ingredients. Publicly available toxicity information.

Revision date: 04-Jan-2017

Product Stewardship Hazard Communication

Prepared by: Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet
